AD/PD™ 2025: Striving for a Better Future for Everyone Affected by Neurodegenerative Diseases
In early April, the capital of Austria, Vienna, hosted one of the most significant events — the International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD™ 2025).
The AD/PD™ Conference is a platform where the brightest minds gather to explore the latest research, clinical trials, and treatment methods for Alzheimer’s and Parkinson’s diseases. From presenting groundbreaking ideas to sharing the most recent advancements in therapy — innovation and collaboration were the main themes of the event.
The International Conference on Alzheimer’s and Parkinson’s Diseases is a global meeting place for medical and scientific professionals from around the world working in the field of neurodegeneration. From basic scientists to clinical researchers, from recognized leaders to promising young talents — the event brought together a diverse range of participants. AD/PD™ 2025 uniquely united various neurodegenerative diseases under one roof, exploring their similarities and differences, with a special focus on disease mechanisms, prevention, and therapy.
A total of 5,574 delegates from over 70 countries participated in the conference, including Austria, Sweden, Norway, Denmark, Portugal, the Netherlands, the United Kingdom, the USA, Canada, Brazil, Spain, Italy, Switzerland, China, South Korea, India, Australia, New Zealand, and others. The scientific program was widely regarded as both stimulating and enriching.
The ongoing success of AD/PD™ 2025 meetings is attributed to several key factors:
- A high-quality scientific program covering the latest research, developments, and treatments, with a focus on Alzheimer’s, Parkinson’s, and related neurological disorders.
- An interdisciplinary community of participants, including both clinical and basic researchers, as well as experienced scientists and emerging young talents.
- An international scientific advisory board with a wide range of expertise in Alzheimer’s, Parkinson’s, and related conditions.
- A consistent effort to foster an environment conducive to interaction, idea exchange, and networking among all attendees.
- Young Investigator Awards designed to encourage and support early-career scientists to attend the conference.
At this prestigious conference, Asfendiyarov Kazakh National Medical University was represented by the Department of Neurology, headed by Professor S.T. Turuspekova, the Chief Neurologist of the Ministry of Health of the Republic of Kazakhstan. The department presented a report titled:
“Neuropeptides with Neurotrophic Effects and Phospholipids in the Treatment of Parkinson’s Disease.”
The presentation was the result of collaborative work by the department’s team: Professor E.S. Nurguzhaev, Assistant Professor B.K. Demessinova, Associate Professor R.B. Nurzhanova, and Assistant N.K. Mamashayeva.
The research focused on identifying effective and accessible tools to expand therapeutic options for correcting motor and cognitive impairments in patients with Parkinson’s disease through the use of a combination of neuropeptides with neurotrophic factors and hypothalamic phospholipids. Parkinson’s disease remains one of the most disabling conditions, significantly reducing the quality of life for both patients and their families.
Kazakhstan’s delegation was also represented by colleagues from the Department of Internal Medicine of the University Medical Center in Astana — Professor L.B. Kuanova and Resident Zh. Nugmanova, who presented the results of their research on amyotrophic lateral sclerosis (ALS) in Kazakhstan.
The AD/PD™ 2025 International Conference on Alzheimer’s and Parkinson’s Diseases provided an excellent opportunity to meet and hear from leading global experts, discuss the latest news and trends in the field, showcase our own work, and receive valuable feedback.
